Clinical landscape of LAG-3-targeted therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical landscape of LAG-3-targeted therapy

Published:2022-06 Issue: Volume:14 Page:100079
ISSN:2590-0188
Container-title:Immuno-Oncology and Technology
language:en
Short-container-title:Immuno-Oncology and Technology

Author:

Chocarro L.,Blanco E.,Arasanz H.,Fernández-Rubio L.,Bocanegra A.,Echaide M.,Garnica M.,Ramos P.,Fernández-Hinojal G.,Vera R.,Kochan G.,Escors D.

Funder

Gobierno de Navarra Departamento de Salud

Gobierno de Navarra Direccion General de Industria Energia y Proyectos Estrategicos S3

Publisher

Elsevier BV

Subject

Oncology,Immunology and Allergy

Reference105 articles.

1. LAG3 (CD223) as a cancer immunotherapy target;Andrews;Immunol Rev,2017

2. Understanding LAG-3 signaling;Chocarro;Int J Mol Sci,2021

3. T cell major histocompatibility complex class II molecules down-regulate CD4+ T cell clone responses following LAG-3 binding;Huard;Eur J Immunol,1996

4. Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes;Huard;Eur J Immunol,1994

5. Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3;Workman;J Immunol,2002

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking therapeutic potential: Targeting lymphocyte activation Gene-3 (LAG-3) with fibrinogen-like protein 1 (FGL1) in systemic lupus erythematosus;Journal of Translational Autoimmunity;2024-12

2. Advances in immunotherapy for breast cancer and feline mammary carcinoma: From molecular basis to novel therapeutic targets;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

3. Dissociation of LAG-3 inhibitory cluster from TCR microcluster by immune checkpoint blockade;Frontiers in Immunology;2024-08-21

4. PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets;EMBO Molecular Medicine;2024-07-19

5. The World of Immunotherapy Needs More Than PD-1/PD-L1—Two of the New Kids on the Block: LAG-3 and TIGIT;Onco;2024-07-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3